Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2018

View Archived Issues

Cellenkos manufacturing facility is successfully registered as GMP compliant with the FDA

Acesion Pharma cleared to conduct phase I study of AP-30663

Janssen submits MAA to EMA for apalutamide for nonmetastatic CRPC

Phase II trials of BI-409306 in Alzheimer's disease do not meet efficacy endpoints

Novo Nordisk's Ozempic approved in E.U.

Boehringer Ingelheim initiates phase I study of BI-1291583

Aravive studies AVB-S6-500 in healthy volunteers

Lundbeck updates progress of fourth quarter 2017

Tychan initiates phase Ia trial of first-in-class Zika antibody tyzivumab

Puma presents clinical data on neratinib in patients with HER2/3 mutant cancers

Phase III quality of life data reported for turoctocog alfa pegol in hemophilia A

Kissei presents novel CGRP antagonists

Retrophin divulges new pantetheine derivatives for neurodegeneration

New phase I/II trial evaluates lentiviral gene transfer for SCID-X1

Achaogen discloses novel ACC inhibitors for bacterial infections

Novel USP19 inhibitors presented by Almac Discovery

Toray Industries identifies MALT1 inhibitors

Roivant and Poxel sign development and license agreement for imeglimin

Seattle Genetics and Pieris Pharmaceuticals enter immune-oncology collaboration

Scholar Rock's SRK-015 antibody inhibits muscle wasting by binding myostatin precursors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...